The Effect of Biological Treatment on Stress Parameters Determined in Saliva in Patients with Severe Psoriasis

被引:3
作者
Foks-Ciekalska, Aleksandra [1 ]
Jarzab, Jerzy [1 ]
Hadas, Ewa [1 ]
Swietochowska, Elzbieta [2 ]
Gumieniak, Kamila [3 ]
Ciekalski, Wiktor [4 ]
Bozek, Andrzej [1 ]
机构
[1] Med Univ Silesia, Clin Dept Internal Dis Dermatol & Allergol Zabrze, PL-40055 Katowice, Poland
[2] Med Univ Silesia, Fac Med Sci Zabrze, Dept Med & Mol Biol, Ul Jordana 19, PL-41808 Zabrze, Poland
[3] Municipal Hosp 4, Dept Internal Med Nephrol Subvis, PL-44100 Gliwice, Poland
[4] Municipal Hosp, Dept Internal Med, PL-41803 Zabrze, Poland
来源
MEDICINA-LITHUANIA | 2023年 / 59卷 / 04期
关键词
psoriasis; stress; psychodermatology; saliva; QUALITY-OF-LIFE; ALPHA-AMYLASE; CHROMOGRANIN-A; PSYCHOLOGICAL STRESS; HEALTH; REACTIVITY; CORTISOL; IMMUNITY; OUTCOMES; INDEX;
D O I
10.3390/medicina59040692
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: In psoriatic patients, stress is the most common aggravating factor. Despite the use of quality-of-life assessment questionnaires, diagnosing stress in psoriatic patients is not a flawless procedure. This study aimed to assess the usefulness of potential stress biomarkers in saliva for monitoring the treatment of psoriasis. Materials and methods: A total of 104 adult patients with severe psoriasis were included and randomly treated via biological treatment or symptomatic therapy: 84 received biological treatment, with 20 formed a control group receiving symptomatic therapy. The administered biological treatment was adalimumab, whilst in controls calcipotriol/betamethasone dipropionate topical gel and emollients were used. Patients were monitored monthly with a dermatological examination and the dispensing of a biological drug. During each of the four visits, the severity of the disease was assessed (PASI, BSA, and DLQI), and a sample of the patient's saliva was taken. In all the participants, the saliva concentrations of immunoglobulin A (sIgA), alpha-amylase (sAA), and chromogranin A (CgA) were measured. Results: The majority of patients in both the study and control groups achieved clinical improvement, though favoring the group receiving biological treatment. The concentration of sIgA in the saliva was constantly increasing in the study group during subsequent visits (Fr = 27.26; p < 0.001). Meanwhile, there were no statistically significant changes in the control group during the same follow-up period (Fr = 6.66; p = 0.084). Levels of sAA underwent statistically significant changes in both groups (Fr = 58.02; p < 0.001-study group and Fr = 13.74; p = 0.003-control group). In the study group, a steady, statistically significant increase in sAA was observed from the first to the third visit. In the study group, a downward trend in CgA concentration was observed. In the control group, no significant differences in the level of CgA were obtained. Conclusions: sIgA, sAA, and CgA are potential markers of the severity of psoriasis and the associated stress reaction. Based on the presented observations, only sIgA and CgA seem to be valuable biomarkers for monitoring the effectiveness of the systemic treatment of psoriasis.
引用
收藏
页数:10
相关论文
共 50 条
[31]   It is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis [J].
Umar, Nasir ;
Schoellgen, Ina ;
Terris, Darcey D. .
PATIENT PREFERENCE AND ADHERENCE, 2012, 6 :187-194
[32]   Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice [J].
Armesto, Susana ;
Coto-Segura, Pablo ;
Mayorga, Jesus ;
Illaro, Aitziber ;
Santos-Juanes, Jorge .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (01) :49-53
[33]   Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study) [J].
Kim, Dong Hyun ;
Son, Sang Wook ;
Jeong, Ki-Heon ;
Ahn, Jiyoung ;
Lee, Eun-So ;
Kim, Il-Hwan ;
Ha Lee, Un ;
Park, Hai-Jin ;
Ko, Joo Yeon ;
Kim, Byung-Soo ;
Kim, Jin Ju ;
Rashid, Javed ;
Kim, Kwang Joong .
ANNALS OF DERMATOLOGY, 2023, 35 (02) :107-115
[34]   Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept [J].
Ortonne, J. -P. ;
Taieb, A. ;
Ormerod, A. D. ;
Robertson, D. ;
Foehl, J. ;
Pedersen, R. ;
Molta, C. ;
Freundlich, B. .
BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 (05) :1190-1195
[35]   Short term efficacy of biological treatment for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis [J].
Ismail, Omar ;
Jaber, Kamel ;
Jaber, Yazan ;
Froukh, Ubadah ;
Younis, Ahmad ;
Albdour, Karam ;
Momani, Yazan ;
Almaani, Noor .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 316 (10)
[36]   Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis [J].
Mastorino, Luca ;
Siliquini, Niccolo ;
Avallone, Gianluca ;
Ortoncelli, Michela ;
Quaglino, Pietro ;
Dapavo, Paolo ;
Ribero, Simone .
DERMATOLOGY REPORTS, 2022, 14 (03)
[37]   Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan [J].
Tada, Yayoi ;
Soliman, Ahmed M. ;
Ishii, Kanako ;
Sakuma, Ryuta ;
Pinter, Andreas ;
Davis, Matthew ;
Nunag, Dominic ;
Buessing, Marric ;
Puig, Luis ;
Imafuku, Shinichi .
EXPERIMENTAL DERMATOLOGY, 2024, 33 (05)
[38]   Evaluation of stress biomarkers and electrolytes in saliva of patients undergoing fixed orthodontic treatment [J].
Silva Andrade, Annicele ;
Marcon Szymanski, Mariana ;
Hashizume, Lina N. ;
Santos Mundstock, Karina ;
Ferraz Goularte, Jeferson ;
Hauber Gameiro, Gustavo .
MINERVA STOMATOLOGICA, 2018, 67 (04) :172-178
[39]   Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation [J].
Ruggiero, Angelo ;
Potestio, Luca ;
Martora, Fabrizio ;
Villani, Alessia ;
Comune, Rosita ;
Megna, Matteo .
EXPERT OPINION ON DRUG SAFETY, 2023, 22 (05) :355-362
[40]   Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis [J].
Skoie, Inger Marie ;
Dalen, Ingvild ;
Omdal, Roald .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (04) :493-502